Research programme: Ebola immunotherapeutics - Emergent BioSolutions

Drug Profile

Research programme: Ebola immunotherapeutics - Emergent BioSolutions

Alternative Names: Anti-Ebola monoclonal antibody - Emergent Biosciences; Ebola hyperimmune product - Emergent BioSciences; Modified vaccinia Ankara Ebola Zaire vaccine; MVA EBOZ; MVA-Ebola vaccine - Emergent BioSciences

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Emergent BioSolutions
  • Class Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 20 Jul 2015 Emergent Biosolutions awarded BARDA for the development of Ebola monoclonal antibodies
  • 06 Mar 2015 Preclinical trials in Ebola virus infections in USA before March 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top